Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

372 ARTÍCULOS , VIENDO DEL 1 AL 15

Cellular and molecular actions of Methylene Blue in the nervous system

Oz M, Lorke DE, Hasan M, Petroianu GA.

Med Res Rev. 2011 Jan;31(1):93-117. doi: 10.1002/med.20177.

Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease

Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T.

Neurobiol Aging. 2011 Sep;32(9):1626-33. doi: 10.1016/j.neurobiolaging.2009.10.009. Epub 2009 Nov 17.

TGF-β1 pathway as a new target for neuroprotection in Alzheimer's disease

Caraci F, Battaglia G, Bruno V, Bosco P, Carbonaro V, Giuffrida ML, Drago F, Sortino MA, Nicoletti F, Copani A.

CNS Neurosci Ther. 2011 Aug;17(4):237-49. doi: 10.1111/j.1755-5949.2009.00115.x. Epub 2009 Nov 19.

Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin

Alvarez XA, Cacabelos R, Sampedro C, Aleixandre M, Linares C, Granizo E, Doppler E, Moessler H.

Eur J Neurol. 2011 Jan;18(1):59-68. doi: 10.1111/j.1468-1331.2010.03092.x.

Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment

Wattmo C, Wallin ÅK, Londos E, Minthon L.

Alzheimer Dis Assoc Disord. 2011 Jan-Mar;25(1):63-72. doi: 10.1097/WAD.0b013e3181f5dd97.

Non-cholinergic pharmacotherapy approaches to Alzheimer's disease: the use of non-steroidal anti-inflammatory drugs

Tsartsalis S, Panagopoulos PK, Mironidou-Tzouveleki M.

CNS Neurol Disord Drug Targets. 2011 Feb;10(1):133-9. doi: 10.2174/187152711794488629.

Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease

Lee JH, Sevigny J.

Alzheimer Dis Assoc Disord. 2011 Jan-Mar;25(1):58-62. doi: 10.1097/WAD.0b013e3181f32829.

Recent developments in tau-based therapeutics for neurodegenerative diseases

Medina M.

Recent Pat CNS Drug Discov. 2011 Jan;6(1):20-30. doi: 10.2174/157488911794079091.

Soothing the inflamed brain: effect of non-steroidal anti-inflammatory drugs on Alzheimer's disease pathology

Hoozemans JJ, Veerhuis R, Rozemuller JM, Eikelenboom P.

CNS Neurol Disord Drug Targets. 2011 Feb;10(1):57-67. doi: 10.2174/187152711794488665.

PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease

Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, Galasko D.

Alzheimer Dis Assoc Disord. 2011 Jul-Sep;25(3):206-12. doi: 10.1097/WAD.0b013e318204b550.

Oral silicon supplementation: an effective therapy for preventing oral aluminum absorption and retention in mammals

Domingo JL, Gómez M, Colomina MT.

Nutr Rev. 2011 Jan;69(1):41-51. doi: 10.1111/j.1753-4887.2010.00360.x.

Therapeutic targets in Alzheimer's disease and related tauopathies

Corbo CP, Alonso Adel C.

Prog Mol Biol Transl Sci. 2011;98:47-83. doi: 10.1016/B978-0-12-385506-0.00002-8.

[Pathological changes induced by amyloid-β in Alzheimer's disease]

Takata K, Kitamura Y, Taniguchi T.

Yakugaku Zasshi. 2011 Jan;131(1):3-11. doi: 10.1248/yakushi.131.3.

Voltage-dependent anion channel as a resident protein of lipid rafts: post-transductional regulation by estrogens and involvement in neuronal preservation against Alzheimer's disease

Herrera JL, Diaz M, Hernández-Fernaud JR, Salido E, Alonso R, Fernández C, Morales A, Marin R.

J Neurochem. 2011 Mar;116(5):820-7. doi: 10.1111/j.1471-4159.2010.06987.x. Epub 2011 Jan 7.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias